Eda R, Sugiyama H, Hopp R J, Bewtra A K, Townley R G
Allergic Disease Center, Creighton University School of Medicine, Omaha, Nebraska.
Ann Allergy. 1993 Oct;71(4):373-8.
We investigated the in vitro effect of loratadine, a new nonsedating H1 histamine antagonist, on the eosinophil functions of chemotaxis, superoxide anion (O2-) generation and eosinophil cationic protein (ECP) release, using purified eosinophils obtained from allergic patients. Loratadine significantly attenuated platelet-activating factor (PAF)-induced eosinophil chemotaxis and O2- generation at therapeutic concentrations (equivalent to serum concentrations after single oral administration of 20 mg or 40 mg). Loratadine, however, had no effect on PAF-induced ECP release. These findings suggest that loratadine has a direct inhibitory effect on eosinophil activation and may be beneficial in the therapy of allergic disorders with its anti-allergic properties.
我们使用从过敏患者中获得的纯化嗜酸性粒细胞，研究了新型非镇静性H1组胺拮抗剂氯雷他定对嗜酸性粒细胞趋化性、超氧阴离子（O2-）生成和嗜酸性粒细胞阳离子蛋白（ECP）释放功能的体外作用。氯雷他定在治疗浓度（相当于单次口服20mg或40mg后的血清浓度）下可显著减弱血小板活化因子（PAF）诱导的嗜酸性粒细胞趋化性和O2-生成。然而，氯雷他定对PAF诱导的ECP释放没有影响。这些发现表明氯雷他定对嗜酸性粒细胞活化具有直接抑制作用，并且其抗过敏特性可能对过敏性疾病的治疗有益。
